Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013 Jun; 11(2):100-6.

View in: PubMed

© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.